GWSA
RPRX icon

Global Wealth Strategies & Associates’s Royalty Pharma RPRX Stock Holding History

Global Wealth Strategies & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-225
Closed -$6.37K – 418
2024
Q3 		$6.37K Hold
225
– – ﹤0.01% 221
2024
Q2 		$5.93K Hold
225
– – ﹤0.01% 208
2024
Q1 		$6.83K Buy
+225
New +$6.63K ﹤0.01% 203

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Global Wealth Strategies & Associates's RPRX Position: Q4 2024 in Review

Global Wealth Strategies & Associates sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 225 shares — an estimated $6.37K sold.

Global Wealth Strategies & Associates first reported a position in RPRX in Q1 2024 and held it in 3 quarters. The position peaked at $6.83K in Q1 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Global Wealth Strategies & Associates reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Global Wealth Strategies & Associates sold 225 Royalty Pharma shares in Q4 2024, an estimated $6.37K.
  • Global Wealth Strategies & Associates first reported a position in Royalty Pharma in Q1 2024 and held it in 3 quarters.
  • Global Wealth Strategies & Associates's Royalty Pharma position peaked at $6.83K in Q1 2024.
  • 417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Global Wealth Strategies & Associates's 13F filing for Q4 2024, filed 2 Jan 2025.